Igaunija - igauņu - Ravimiamet

vetoquinol s.a. - tseftiofuur - süstesuspensioon - 50mg 1ml 50ml 1tk; 50mg 1ml 100ml 1tk; 50mg 1ml 250ml 1tk

Igaunija - igauņu - Ravimiamet

laboratorios hipra s.a. - tseftiofuur - süstesuspensioon - 50mg 1ml 250ml 1tk; 50mg 1ml 100ml 12tk; 50mg 1ml 100ml 10tk

Igaunija - igauņu - Ravimiamet

kepro b.v. - tseftiofuur - süstesuspensioon - 50mg 1ml 250ml 1tk

Igaunija - igauņu - Ravimiamet

ceva sante animale - tseftiofuur - süstelahuse pulber ja lahusti - 50mg 1ml 1g 1tk; 50mg 1ml 4g 1tk

Igaunija - igauņu - Ravimiamet

laboratorios calier s.a. - tseftiofuur - süstesuspensioon - 50mg 1ml 100ml 1tk; 50mg 1ml 250ml 1tk

Eiropas Savienība - igauņu - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - muud antineoplastilised ained - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Igaunija - igauņu - Ravimiamet

norbrook laboratories (ireland) limited - tseftiofuur - süstelahuse pulber ja lahusti - 50mg 1ml 1000mg 1tk; 50mg 1ml 4000mg 12tk; 50mg 1ml 4000mg 1tk; 50mg 1ml 1000mg 6tk; 50mg 1ml 4000mg 6tk

Igaunija - igauņu - Ravimiamet

dechra regulatory b.v. - klindamütsiin - närimistablett - 220mg 100tk

Igaunija - igauņu - Ravimiamet

dechra regulatory b.v. - klindamütsiin - närimistablett - 440mg 10tk; 440mg 30tk; 440mg 20tk; 440mg 250tk; 440mg 80tk; 440mg 100tk

Igaunija - igauņu - Ravimiamet

dechra regulatory b.v. - klindamütsiin - närimistablett - 55mg 40tk; 55mg 100tk